Tag: Takeda

Takeda Acquired Exclusive Global License to Develop Investigational Medicine CNP-101/TAK-101

takeda
Takeda Pharmaceutical Company Limited and COUR Pharmaceutical Development Company, Inc. announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational ...

Takeda to Sell Assets to Acino for $200m

Takeda Pharmaceutical Company Limited announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near ...

Takeda Broke into Top-20 Largest Pharmas after Shire Merger

takeda
Takeda broke into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger with Shire Pharma earlier this year, according to a new analysis using market capitalisati...

Goldfinch Bio Announced License Agreement with Takeda

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced it entered into a license ag...

Prometheus and Takeda to Discover Novel Therapies for Inflammatory Bowel Disease

Prometheus Biosciences, Inc., a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics ...

Evotec Announced Strategic Drug Discovery Collaboration with Takeda

takeda
Evotec SE announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Under the collaboration, the parties aim to establish at least five drug discovery ...

Trintellix® for Depression Treatment Approved in Japan

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S jointly announced that the MHLW of Japan approved Trintellix® (vortioxetine) for the treatment of depression and depressed state. Vortioxetine...

NICE Recommended Use of Takeda’s Takhzyro on NHS

takeda
The National Institute for Health and Clinical Excellence (NICE) - a health technology appraisal body in England and Wales - has recommended the use of Takeda’s Takhzyro (lanadelumab) on the NHS. A...

Takeda to Recall NATPARA® in the United States

Takeda Pharmaceutical Company Limited announced that the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). This rec...

Expansion of Drug Discovery Collaboration with Takeda Announced by Schrödinger

drug discovery
Schrödinger announced the expansion of multi-year, multi-target drug discovery collaboration with Takeda, as well as Schrödinger’s achievement of the first significant preclinical milestone for the co...

Emendo Achieved Milestone of Collaboration for Takeda’s OMNI Nuclease Program

takeda hq tokyo
Emendo Biotherapeutics announced that the company achieved the first milestone as laid out in the agreements with Takeda Pharmaceutical Company Limited, resulting in the transfer of the second half of...

Sosei & Takeda to Develop Novel Molecules

takeda
Sosei Group Corporation announces that it has entered into a strategic multi-target partnership with Takeda Pharmaceutical Company Limited, to discover, develop and commercialize novel molecules, incl...

Takeda Announced Results of the VISIBLE 2 Clinical Trials Evaluating Vedolizumab

takeda hq tokyo
Takeda Pharmaceutical Company Limited announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-sel...

Takeda Openes First API Manufacturing Plant outside Japan

Takeda has officially opened a new manufacturing plant at its site at Grange Castle, in Dublin, Ireland. The company CEO, government ministers and industry officials together with staff and guests ...

Takeda Announced Updated Results from its Phase IIIb/IV Clinical Trial for ADYNOVATE®

takeda
Takeda Pharmaceutical Company Limited, R&D-driven, global biopharmaceutical company with a leadership position in rare diseases, has announced updated results from its phase IIIb/IV clinical trial...

Partnership for New Parkinson’s Disease Treatment

The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parki...